生物制剂在坏疽性脓皮病治疗中的研究进展  

Research Progress of Biological Agents in the Treatment of Gangrenous Pyoderma

作　　者：曾琳茜 姚越 黄欣 张国强[1] ZENG Linxi;YAO Yue;HUANG Xin;ZHANG Guoqiang(Department of Dermatology,the First Hospital of Hebei Medical University,Shijiazhuang 050031,China)

机构地区：[1]河北医科大学第一医院皮肤科,河北石家庄050031

出　　处：《中国皮肤性病学杂志》2023年第9期1081-1084,共4页The Chinese Journal of Dermatovenereology

基　　金：河北医科大学2018年高等教育教学改革项目(2018-88)。

摘　　要：坏疽性脓皮病(PG)是一种少见的溃疡性皮肤病,发病机制尚不明确,在治疗上有一定的难度。目前较为常用的药物是糖皮质激素和免疫抑制剂,但仍有部分患者无明显疗效。近期研究发现,生物制剂治疗PG有效,特别是对于一些难治性的PG患者,也可以达到较好的治疗效果,而且还有良好的安全性和耐受性,目前可用于治疗PG的生物制剂包括TNF-α抑制剂、IL-1和IL-12/23等拮抗剂,这些药物将为PG患者的治疗带来新的曙光。Pyoderma gangrenosum(PG) is a rare ulcerative skin disease,with unclear pathogenesis difficulty in the treatment.Currently,corticosteroids and immunosuppressants are commonly used,which,however,have no obvious effect in several patients.Recent studies have found that biological agents are effective in the treatment of PG,especially for some refractory PG patients,and can also achieve good therapeutic effect,with good safety and tolerance.The commonly used biological agents for the treatment of PG include TNF-α inhibitors,interleukin(IL)-1 and IL-12/23 antagonists,which will offer new insight into the treatment of PG patients.

关 键 词：坏疽性脓皮病 治疗 生物制剂 TNF-Α抑制剂 

分 类 号：R758.6[医药卫生—皮肤病学与性病学]